{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:13Z","timestamp":1792788553939,"version":"4.5.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Trio Health"},{"name":"Trio Health"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0228847","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T13:40:05Z","timestamp":1581601205000},"page":"e0228847","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":43,"title":["Real-world efficacy of direct acting antiviral therapies in patients with HIV\/HCV"],"prefix":"10.1371","volume":"15","author":[{"given":"Sonia Vibhakar","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dushyantha T.","family":"Jayaweera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri N.","family":"Althoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Eron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0462-5505","authenticated-orcid":true,"given":"Janna","family":"Radtchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Moyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Sax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Mounzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Elion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"pone.0228847.ref001","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12072-018-9896-4","article-title":"A changing paradigm: management and treatment of the HCV\/HIV-coinfected patient","volume":"12","author":"A Abutaleb","year":"2018","journal-title":"Hepatology International"},{"issue":"7","key":"pone.0228847.ref002","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis","volume":"16","author":"L Platt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"pone.0228847.ref003","unstructured":"World Health Organization. HIV and hepatitis coinfections. https:\/\/www.who.int\/hiv\/topics\/hepatitis\/en\/ Cited December 20 2018."},{"key":"pone.0228847.ref004","unstructured":"Centers for Disease Control and Prevention. Epidemiology and Prevention of HIV and Viral Hepatitis Co-infections. https:\/\/www.cdc.gov\/hiv\/pdf\/library\/factsheets\/hiv-viral-hepatitis.pdf. Cited December 20 2018."},{"issue":"3","key":"pone.0228847.ref005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/MOG.0000000000000347","article-title":"Update in HIV\/HCV Co-Infection in the Direct Acting Antiviral Era","volume":"33","author":"EG Meissner","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"pone.0228847.ref006","first-page":"369","article-title":"Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study","volume":"160","author":"V Lo Re","year":"2014","journal-title":"Ann Intern Med"},{"issue":"3","key":"pone.0228847.ref007","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/hep.26741","article-title":"Fibrosis progression in human immunodeficiency virus\/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs","volume":"59","author":"MA Konerman","year":"2014","journal-title":"Hepatology"},{"issue":"12","key":"pone.0228847.ref008","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cgh.2010.08.004","article-title":"Similar progression of fibrosis between HIV\/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples","volume":"8","author":"RK Sterling","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"pone.0228847.ref009","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2012.12.026","article-title":"Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997","volume":"144","author":"J Van der Helm","year":"2013","journal-title":"Gastroenterology"},{"issue":"18","key":"pone.0228847.ref010","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1097\/QAD.0000000000001646","article-title":"Hepatitis B, Hepatitis C, and mortality among HIV-positive individuals","volume":"31","author":"AC Thornton","year":"2017","journal-title":"AIDS"},{"key":"pone.0228847.ref011","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study","volume":"166","author":"R Weber","year":"2006","journal-title":"Arch Intern Med"},{"issue":"10","key":"pone.0228847.ref012","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1086\/644771","article-title":"Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression","volume":"49","author":"TY Chen","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0228847.ref013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","article-title":"Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy","volume":"44","author":"N Brau","year":"2006","journal-title":"J Hepatol"},{"issue":"9","key":"pone.0228847.ref014","first-page":"1160","article-title":"Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras","volume":"63","author":"MB Klein","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pone.0228847.ref015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/hiv.12502","article-title":"Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV","volume":"18","author":"A Mena","year":"2017","journal-title":"HIV Med"},{"issue":"3","key":"pone.0228847.ref016","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.29642","article-title":"Hepatitis C and Human Immunodeficiency Virus coinfection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult-to-Treat Population","volume":"67","author":"C Sikavi","year":"2018","journal-title":"Hepatology"},{"issue":"9939","key":"pone.0228847.ref017","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011: a multicohort collaboration","volume":"384","author":"CJ Smith","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"pone.0228847.ref018","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"RT Chung","year":"2004","journal-title":"N Engl J Med"},{"issue":"18","key":"pone.0228847.ref019","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","article-title":"Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic","volume":"20","author":"SH Mehta","year":"2006","journal-title":"AIDS"},{"key":"pone.0228847.ref020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1146\/annurev.med.59.081906.081110","article-title":"The challenge of hepatitis C in the HIV-infected person","volume":"59","author":"DL Thomas","year":"2008","journal-title":"Annu. Rev. Med"},{"issue":"Suppl 1","key":"pone.0228847.ref021","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/cid\/ciw219","article-title":"Management of Hepatitis C\/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy","volume":"63","author":"DL Wyles","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pone.0228847.ref022","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/cid\/cix111","article-title":"Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus\/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice","volume":"64","author":"D Bhattacharya","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"8","key":"pone.0228847.ref023","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"S Naggie","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0228847.ref024","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial","volume":"313","author":"MS Sulkowski","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"pone.0228847.ref025","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"DL Wyles","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0228847.ref026","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: An Open-Label, Phase 3 Study","volume":"65","author":"D Wyles","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0228847.ref027","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"MS Sulkowski","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"pone.0228847.ref028","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/apc.2014.0033","article-title":"Barriers to hepatitis C antiviral therapy in HIV\/HCV co-infected patients in the United States: a review","volume":"28","author":"CU Oramasionwu","year":"2014","journal-title":"AIDS Patient Care STDS"},{"key":"pone.0228847.ref029","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. http:\/\/aidsinfo.nih.gov Cited December 7 2018."},{"key":"pone.0228847.ref030","unstructured":"National Hepatitis Roundtable. Hepatitis C: State of Medicaid Access. https:\/\/stateofhepc.org\/wp-content\/uploads\/2017\/10\/State-of-Access-Infographic.pdf Cited December 7 2018."},{"key":"pone.0228847.ref031","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"S Barua","year":"2015","journal-title":"Ann Intern Med"},{"key":"pone.0228847.ref032","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1093\/jac\/dkw203","article-title":"High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV\/HCV-coinfected patients: a real-world perspective","volume":"71","author":"C Hawkins","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"pone.0228847.ref033","doi-asserted-by":"crossref","first-page":"ofv168","DOI":"10.1093\/ofid\/ofv168","article-title":"The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients with Ongoing Barriers to Care","volume":"2","author":"ER Cachay","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"pone.0228847.ref034","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/cid\/ciw119","article-title":"Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV","volume":"62","author":"D Del Bello","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0228847.ref035","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12429","article-title":"Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV\/HIV-coinfected patients: real-life safety and efficacy","volume":"18","author":"L Milazzo","year":"2017","journal-title":"HIV Med"},{"key":"pone.0228847.ref036","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/cid\/ciw379","article-title":"All-oral Direct-acting Antiviral Regimens in HIV\/Hepatitis C Virus-coinfected Patients with Cirrhosis Are Efficient and Safe: Real-life Results from the Prospective ANRS CO13-HEPAVIH Cohort","volume":"63","author":"P Sogni","year":"2016","journal-title":"Clin Infect Dis"},{"key":"pone.0228847.ref037","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/QAD.0000000000000903","article-title":"Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir","volume":"30","author":"K Townsend","year":"2016","journal-title":"Aids"},{"key":"pone.0228847.ref038","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/cid\/ciw447","article-title":"Treatment of Hepatitis C Virus in HIV-Coinfected Individuals in Real-world Clinical Settings: Results From 2 Large HIV Care Clinics","volume":"63","author":"SE Rowan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"pone.0228847.ref039","unstructured":"American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C http:\/\/www.hcvguidelines.org Cited December 21 2018."},{"key":"pone.0228847.ref040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/cid\/cit197","article-title":"Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984\u20132011","volume":"57","author":"MD Witt","year":"2013","journal-title":"Clin Infect Dis"},{"key":"pone.0228847.ref041","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/QAD.0b013e3283471cce","article-title":"The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007","volume":"25","author":"JJ Van der Helm","year":"2011","journal-title":"AIDS"},{"issue":"28","key":"pone.0228847.ref042","first-page":"945","article-title":"Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men\u2014New York City, 2005\u20132010","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR. Morbidity and mortality weekly report"},{"key":"pone.0228847.ref043","unstructured":"Braun D, Hampel B. Nguyen H, Flepp M, Stoeckle M, B\u00e9guelinet C, et al. A Treatment as Prevention Trial to Eliminate HCV in HIV+ MSM: The SWISS HCVREE Trial. Conference on Retroviruses and Opportunistic Infections (CROI) 2018 abstract 81LB. http:\/\/www.croiconference.org\/sessions\/treatment-prevention-trial-eliminate-hcv-hiv-msm-swiss-hcvree-trial Cited December 7 2018."},{"issue":"5","key":"pone.0228847.ref044","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000179","article-title":"The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention","volume":"10","author":"NK Martin","year":"2015","journal-title":"Current Opinion in HIV and AIDS"},{"issue":"11","key":"pone.0228847.ref045","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/QAD.0000000000001522","article-title":"MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection","volume":"31","author":"E Hoornenborg","year":"2017","journal-title":"AIDS"},{"key":"pone.0228847.ref046","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1097\/QAD.0000000000000834","article-title":"Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men","volume":"29","author":"H Hagan","year":"2015","journal-title":"AIDS"},{"key":"pone.0228847.ref047","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/apc.2015.0314","article-title":"HIV and Hepatitis C Virus Screening Practices in a Geographically Diverse Sample of American Community Health Centers","volume":"30","author":"KH Mayer","year":"2016","journal-title":"AIDS Patient Care STDS"},{"key":"pone.0228847.ref048","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10865-016-9778-y","article-title":"Assessment of factors associated with the quality of life of patients living with HIV\/HCV co-infection","volume":"39","author":"M Pereira","year":"2016","journal-title":"J Behav Med"},{"issue":"1","key":"pone.0228847.ref049","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.29814","article-title":"All-Oral Direct-Acting Antiviral Therapy Against Hepatitis C Virus (HCV) in Human Immunodeficiency Virus\/HCV\u2013Coinfected Subjects in Real-World Practice: Madrid Coinfection Registry Findings","volume":"68","author":"J Berenguer","year":"2018","journal-title":"Hepatology"},{"key":"pone.0228847.ref050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jvh.12611","article-title":"Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: The Trip Health Study","volume":"24","author":"EB Tapper","year":"2017","journal-title":"J Viral Hepat"},{"issue":"3","key":"pone.0228847.ref051","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"J Grebely","year":"2018","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"suppl 1","key":"pone.0228847.ref052","article-title":"High SVR in PWID with HCV Despite Imperfect Medication Adherence: Data from the Anchor Study","volume":"68","author":"S Kattakuzhy","year":"2018","journal-title":"Hepatology"},{"issue":"suppl 1","key":"pone.0228847.ref053","article-title":"HCV Reinfection and Injecting Risk Behavior Following Elbasvir\/Grazoprevir Treatment in Patients on Opioid Agonist Therapy: C-Edge Co-STAR Part B","volume":"68","author":"G Dore","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"pone.0228847.ref054","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2009.09.019","article-title":"Effective Treatment of Injecting Drug Users with Recently Acquired Hepatitis C Virus Infection","volume":"138","author":"G Dore","year":"2010","journal-title":"Gastroenterology"},{"issue":"11","key":"pone.0228847.ref055","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/cid\/ciw579","article-title":"Efficacy and Safety of Sofosbuvir\/Velpatasvir in Patients with Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials","volume":"63","author":"J Grebely","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"pone.0228847.ref056","doi-asserted-by":"crossref","first-page":"e0150655","DOI":"10.1371\/journal.pone.0150655","article-title":"Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort","volume":"11","author":"JS Doyle","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"pone.0228847.ref057","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","year":"2018","journal-title":"Journal of Hepatology"},{"issue":"1","key":"pone.0228847.ref058","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/S0168-8278(17)30406-3","article-title":"The PREVAIL Study: Intensive Models of HCV Care for People Who Inject Drugs","volume":"66","author":"AH Litwin","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"pone.0228847.ref059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/00333549161310S201","article-title":"Strategies for expanding access to HBV and HCV testing and care in the United States: The CDC Hepatitis Testing and Linkage to Care Initiative, 2012\u20132014","volume":"131","author":"JW Ward","year":"2016","journal-title":"Public Health Rep"},{"key":"pone.0228847.ref060","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S0168-8278(18)30735-9","article-title":"Untreated HCV in HIV\/HCV Co-Infection: Data from the TRIO Network. abstract THU-294","volume":"68","author":"D Jayaweera","year":"2018","journal-title":"Journal of Hepatology"},{"key":"pone.0228847.ref061","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/cid\/civ1222","article-title":"How Generalizable Are the Results from Trials of Direct Antiviral Agents to People Co-infected with HIV\/HCV in the Real World?","volume":"62","author":"S Saeed","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T13:40:34Z","timestamp":1581601234000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228847"}},"subtitle":[],"editor":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0228847","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]}}}